SynthesisCurrent neuropharmacology2017
Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials.
Synthesis in Current neuropharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Interventions for treating pain and disability in adults with complex regional pain syndrome- an overview of systematic reviews.The Cochrane database of systematic reviews · 2023Pooled it
- Non-opioid Analgesics and Emerging Therapies.Cancer treatment and research · 2021Pooled it
- Marine Algae and Neuroprotection: Unlocking the Therapeutic Potential Against Neurodegenerative Diseases.Phytotherapy research : PTR · 2026Review
- The Potential and Prospects of Marine Drugs in Intervening Nerve-Tumor Crosstalk.Marine drugs · 2026Review
- Efficacy and safety of the CaPain reports · 2025Review
- Can Ziconotide Be Used to Replace Opioids? Exploratory Clinical Experience in 5 Patients Treated in the Pain Unit.Journal of pain research · 2025Article
- A comprehensive review on ziconotide.Heliyon · 2024Review
- A Benefit/Risk Assessment of Intrathecal Ziconotide in Chronic Pain: A Narrative Review.Journal of clinical medicine · 2024Review
- Covalently Binding Adenosine APurinergic signalling · 2024Article
- Ziconotide and psychosis: from a case report to a scoping review.Frontiers in molecular neuroscience · 2024Article
- Role of Cav2.3 (R-type) Calcium Channel in Pain and Analgesia: A Scoping Review.Current neuropharmacology · 2024Article
- The Options for Neuraxial Drug Administration.CNS drugs · 2022Review
- Voltage-dependent CaPflugers Archiv : European journal of physiology · 2022Review
- Therapeutic Potential of Highly Selective AMolecules (Basel, Switzerland) · 2022Review
- Intrathecal Administration of Ziconotide as a Potential Treatment for Chronic Migraines.Cureus · 2022Article
- Animal Venom Peptides Cause Antinociceptive Effects by Voltage-gated Calcium Channels Activity Blockage.Current neuropharmacology · 2022Article
- Uncovering the Mechanisms of Adenosine Receptor-Mediated Pain Control: Focus on the AInternational journal of molecular sciences · 2021Review
- Intrathecal pain management with ziconotide: Time for consensus?Brain and behavior · 2021Article
- Benefits under the Sea: The Role of Marine Compounds in Neurodegenerative Disorders.Marine drugs · 2021Review
- Neuroactive venom compounds obtained fromThe journal of venomous animals and toxins including tropical diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
introductionChronic neuropathic pain is difficult to treat and is often refractory to most modalities of treatment. Ziconotide is a novel, potent, non-opioid, calcium channel blocking agent which has been shown in clinical trials to be effective in treating chronic neuropathic pain.
methodsEMBASE, MEDLINE, CINAHL Plus and Web of Science electronic databases were searched for English language studies. Reference sections of articles were examined for further papers and the manufacturer of ziconotide was contacted for further unpublished data. Three randomised controlled trials in ziconotide monotherapy were included and subjected to a random effects meta-analysis.
resultsAll three studies used the similar main outcome measure (visual analogue scale of pain intensity; VASPI) and were therefore comparable. A Jadad score was performed for each paper. Frequent serious adverse events (SAEs) were observed which resulted in two of the studies revising the protocol. The metaanalysis revealed a pooled odds ratio (responders on ziconotide vs. placebo) of 2.77 (95% CI, 1.37 to 5.59). DISCUSSION: The results suggest that ziconotide is beneficial for pain reduction in chronic neuropathic pain. However, there remain some methodological issues that may call into question the validity of the results. It is evident that more work needs to be conducted to further validate the efficacy of ziconotide and to discover new areas of use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.